BusinessMolecularMD obtains FDA Authorization for the MRDx® BCR-ABL Test as a Companion Diagnostic for Treatment-Free Remission in Ph+ CML-CP Patients Treated with TasignaBy Nasdaq OMXDec 22, 2017, 11:02 PM UTC
